tiprankstipranks
Trending News
More News >
Opthea Limited (AU:OPT)
:OPT
Advertisement

Opthea (OPT) Price & Analysis

Compare
43 Followers

OPT Stock Chart & Stats


Opthea News

OPT FAQ

What was Opthea Limited’s price range in the past 12 months?
Opthea Limited lowest share price was AU$0.41 and its highest was AU$1.17 in the past 12 months.
    What is Opthea Limited’s market cap?
    Opthea Limited’s market cap is AU$738.77M.
      When is Opthea Limited’s upcoming earnings report date?
      Opthea Limited’s upcoming earnings report date is Aug 28, 2025 which is in 20 days.
        How were Opthea Limited’s earnings last quarter?
        Opthea Limited released its earnings results on Feb 27, 2025. The company reported -AU$0.166 earnings per share for the quarter, missing the consensus estimate of -AU$0.025 by -AU$0.141.
          Is Opthea Limited overvalued?
          According to Wall Street analysts Opthea Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does Opthea Limited pay dividends?
            Opthea Limited does not currently pay dividends.
            What is Opthea Limited’s EPS estimate?
            Opthea Limited’s EPS estimate is -0.01.
              How many shares outstanding does Opthea Limited have?
              Opthea Limited has 1,231,287,400 shares outstanding.
                What happened to Opthea Limited’s price movement after its last earnings report?
                Opthea Limited reported an EPS of -AU$0.166 in its last earnings report, missing expectations of -AU$0.025. Following the earnings report the stock price went up 2.674%.
                  Which hedge fund is a major shareholder of Opthea Limited?
                  Currently, no hedge funds are holding shares in AU:OPT

                  Company Description

                  Opthea Limited

                  Opthea Limited (OPT) is a biotechnology company focused on developing treatments for eye diseases. The company operates primarily in the healthcare sector, with its core product being OPT-302, a novel therapy intended for the treatment of wet age-related macular degeneration (wet AMD) and other retinal vascular disorders. Opthea's mission is to enhance vision care by pioneering innovative therapies that address unmet medical needs in ophthalmology.

                  Opthea (OPT) Earnings & Revenues

                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Immutep Ltd
                  Dimerix Limited
                  Race Oncology Ltd.
                  Clarity Pharmaceuticals Ltd.
                  Botanix Pharmaceuticals Limited

                  Ownership Overview

                  0.02%2.78%95.69%
                  0.02%
                  Insiders
                  2.78%
                  Mutual Funds
                  ― Other Institutional Investors
                  95.69% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis